The FDA has convened an advisory committee meeting to review the data on 17 December, and Merck says it anticipates a target action date by the regulator in January 2020. Keytruda has already been ...

Shares of Summit Therapeutics soared 56% to 19.14. It's important to note that ivonescimab uses a different mechanism from ...

The first part of the trial involves escalating doses of TGN-S11 monotherapy, while the second part is assessing the Keytruda combination ... agent whose mechanism of action involves inhibiting ...